Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 19, 2015
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 20, 2014
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apimostinel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 17, 2013
Lead Product(s) : Apimostinel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : The University of Pittsburgh School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Gate Neurosciences, Pittsburgh Partner for Apimostinel Digital Depression Trial
Details : The collaboration aims the initiation of a Phase 2 to assess the potential for extending the efficacy of GATE-202 (apimostinel), a rapid-acting antidepressant drug.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : The University of Pittsburgh School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Gate Neurosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Apimostinel + Automated Neurocognitive Training for Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2024
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Gate Neurosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GATE-202 (apimostinel) is 2nd generation rapid-acting injectable NMDAR modulator program. Previously demonstrated rapid and robust 24-hour antidepressant effects in a Phase 2a MDD study (p=0.0034)
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2022
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Allergan Aesthetics
Deal Size : Inapplicable
Deal Type : Inapplicable
NRX-1074 in Early Course Schizophrenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 11, 2015
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Allergan Aesthetics
Deal Size : Inapplicable
Deal Type : Inapplicable